Antibody Response Induced by Two Doses of ChAdOx1 nCoV-19, mRNA-1273, or BNT162b2 in Liver Transplant Recipients
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Coronavirus disease 2019 (COVID-19) vaccination in immunocompromised, especially transplant recipients, may induce a weaker immune response. But there are limited data on the immune response after COVID-19 vaccination in liver transplant (LT) recipients, especially on the comparison of Ab responses after different vaccine platforms between mRNA and adenoviral vector vaccines. Thus, we conducted a prospective study on LT recipients who received two doses of the ChAdOx1 nCoV-19 (ChAdOx1), mRNA-1273, or BNT162b2 vaccines compared with healthy healthcare workers (HCWs). SARS-CoV-2 S1-specific IgG Ab titers were measured using ELISA. Overall, 89 LT recipients (ChAdOx1, n=16 [18%]) or mRNA vaccines (mRNA-1273 vaccine, n=23 [26%]; BNT162b2 vaccine, n=50 [56%]) received 3 different vaccines. Of them, 16 (18%) had a positive Ab response after one dose of COVID-19 vaccine and 62 (73%) after 2 doses. However, the median Ab titer after two doses of mRNA vaccines was significantly higher (44.6 IU/ml) than after two doses of ChAdOx1 (19.2 IU/ml, p=0.04). The longer time interval from transplantation was significantly associated with high Ab titers after two doses of vaccine (p=0.003). However, mycophenolic acid use was not associated with Ab titers (p=0.53). In conclusion, about 3-quarters of LT recipients had a positive Ab response after 2 doses of vaccine, and the mRNA vaccines induced higher Ab responses than the ChAdOx1 vaccine.
Abstract
Coronavirus disease 2019 (COVID-19) vaccination in immunocompromised, especially transplant recipients, may induce a weaker immune response. But there are limited data on the immune response after COVID-19 vaccination in liver transplant (LT) recipients, especially on the comparison of Ab responses after different vaccine platforms between mRNA and adenoviral vector vaccines. Thus, we conducted a prospective study on LT recipients who received two doses of the ChAdOx1 nCoV-19 (ChAdOx1), mRNA-1273, or BNT162b2 vaccines compared with healthy healthcare workers (HCWs). SARS-CoV-2 S1-specific IgG Ab titers were measured using ELISA. Overall, 89 LT recipients (ChAdOx1, n=16 [18%]) or mRNA vaccines (mRNA-1273 vaccine, n=23 [26%]; BNT162b2 vaccine, n=50 [56%]) received 3 different vaccines. Of them, 16 (18%) had a positive Ab response after one dose of COVID-19 vaccine and 62 (73%) after 2 doses. However, the median Ab titer after two doses of mRNA vaccines was significantly higher (44.6 IU/ml) than after two doses of ChAdOx1 (19.2 IU/ml, p=0.04). The longer time interval from transplantation was significantly associated with high Ab titers after two doses of vaccine (p=0.003). However, mycophenolic acid use was not associated with Ab titers (p=0.53). In conclusion, about 3-quarters of LT recipients had a positive Ab response after 2 doses of vaccine, and the mRNA vaccines induced higher Ab responses than the ChAdOx1 vaccine.
참고문헌 (19)
- "WHO coronavirus (COVID-19) dashboard"[URL]
- Dagan N, "Bnt162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting", N Engl J Med, 384, pp.1412~1423 (2021)
- Abu-Raddad LJ, "Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar", N Engl J Med, 386, pp.1804~1816 (2022)
- "COVID-19 vaccine boosters"[URL]
- Benotmane I, "Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine", Kidney Int, 99, pp.1498~1500 (2021)
- Rozen-Zvi B, "Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients : a prospective cohort study", Clin Microbiol Infect, 27, pp.1173~ (2021)
- Grupper A, "Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus", Am J Transplant, 21, pp.2719~2726 (2021)
- Cucchiari D, "Cellular and humoral response after mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients", Am J Transplant, 21, pp.2727~2739 (2021)
- Rabinowich L, "Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients", J Hepatol, 75, pp.435~438 (2021)
- Thuluvath PJ, "Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases", J Hepatol, 75, pp.1434~1439 (2021)
- Ruether DF, "SARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients", Clin Gastroenterol Hepatol, 20, pp.162~172 (2022)
- Kim JY, "Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural coronavirus disease 2019 infections over a 3-month period", J Infect Dis, 225, pp.777~784 (2022)
- Caillard S, "COVID-19 vaccination in kidney transplant recipients", Nat Rev Nephrol, 17, pp.785~787 (2021)
- Nazaruk P, "Unexpectedly high efficacy of SARS-CoV-2 BNT162b2 vaccine in liver versus kidney transplant recipients-is it related to immunosuppression only?", Vaccines (Basel), 9, pp.1454~ (2021)
- Pahl MV, "Chronic Renal Disease", pp.285~297 (2015), Academic Press
- He X, "Mycophenolic acid-mediated suppression of human CD4+ T cells : more than mere guanine nucleotide deprivation", Am J Transplant, 11, pp.439~449 (2011)
- Boyarsky BJ, "Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients", JAMA, 325, pp.2204~2206 (2021)
- Heidt S, "Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help", Clin Exp Immunol, 159, pp.199~207 (2010)
- Wallin EF, "The calcineurin inhibitor tacrolimus specifically suppresses human T follicular helper cells", Front Immunol, 9, pp.1184~ (2018)